An Israeli researcher says a cost-effective method for making human liver cells offers drug developers better safety evaluation and will “undoubtedly” replace animal testing.
Niche technologies will differentiate CMOs looking for a slice of the steady oral dosage manufacturing industry, according to an industry report from ISR.
Clariant will build a CHF10m ($9.7m) moisture control device plant in Cuddalore, Tamil Nadu to cater for the branded and generic drugmakers operating in India.
Pfizer says it will decide in 2018 whether to split its generics and branded businesses but M&A experts are already predicting how the giant will get rid of its established drugs programme.
Should small pharma firms stick to small CROs? Quintiles and Covance both believe they can offer the personal touch, but Outsourcing-Pharma wants to know what you think?
Teva has teamed with Heptares to develop and commercialise easily-deliverable small-molecule calcitonin gene-related peptide (CGPR) antagonists to treat migraine.
New acquisition Sigma Aldrich will play a part in African growth plans in addition to giving it a presence in the preclinical services sector says Merck*.
Preclinical CRO Biopta will add stem cell programming tech to its offering, expand in Japan and nearly double its workforce under new owner, Reprocell.
The number of pharmaceutical cargo thefts has fallen in recent years, but manufacturers still need to be vigilant according to an expert who says the holidays are a risky period.
As CMOs wait to see the short-term fallout of the Pfizer-Allergan deal, an M&A expert says contract manufacturing will follow the CRO industry in embracing strategic alliances and consolidation.
Restarting production at the former Ben Venue facility in Ohio will be a “significant task” says Xellia Pharmaceuticals which plans to invest after buying the site from Hikma.
Manipulated employee records and English-only training materials were among violations cited by the US FDA at two Indian plants, but Sandoz is confident these will be resolved.
Inconsistent practices and a lack of trust are restricting sponsors from fully realising the potential of CRO strategic partnerships, according to Tufts' Director Kenneth Getz.
Thermofisher Scientific has stopped selling two agars used in pharmaceutical industry control labs, citing a worldwide shortage of the seaweed used to make them.
The US FDA has cleared Ash Stevens to make the API for Takeda's new multiple myeloma drug Ninlaro, which is the first oral proteasome inhibitor to be approved in the country.
Tweaks to EU orphan drug rules (OD) may be needed to accommodate Ebola treatment development and block industry attempts to delay generic entry says the European Commission.
The $160bn Pfizer-Allergan megamerger could lead to booking cancellations in the short-term say analysts, but CROs – especially Icon, Parexel and PPD - should ultimately benefit.
AstraZeneca says it had no worries about giving rival Sanofi a potential blockbuster drug when the two exchanged compound library molecules this month.
US Customs and Border Protection (CBP) says the country of origin of Carlsbad Technology’s acyclovir is where the API is sourced, not the US where the tablets are made.
Cyprotex has expanded its toxicology offering with a new in silico technology it claims will reduce preclinical costs and cut the number of animal studies required.
Juniper Pharmaceuticals has made a “significant capital investment” to expand its Xcelodose powder micro-dosing system to feed demand for Phase I study materials.
A professor who conducted fast-track trials during last year’s Ebola outbreak says next time such trials must be part of humanitarian response… because there will be a next time.
With data becoming growingly important in clinical trials, CROs and sponsors must embrace companies like Apple and Google to manage it, say panellists at PCT Europe.
The CEO of Immuno Biotech who said he only employs “beautiful women” and noted a candidate’s lipstick and high heels on her job application has been fined for sex discrimination.
The US government may require companies running clinical trials to post their informed consent forms publicly, under rules proposed by the Department of Health and Human Services (HHS).
Dyadic has agreed to sell its enzyme-producing fungal expression system and the rest of its industrial technology business to DuPont for $75 million (€70 million).
As World Antibiotics Awareness Week draws attention to the threat of resistance, pharma companies large and small say a worldwide overhaul of payment models will make anti-infective R&D profitable again.
